LIST OF FIGURES

Figures	Title	Page
Figure 1.1	Glia-neuron interactions	3
Figure 1.2	Oligodendrocytes origin and specification in Spinal cord and brain	9
Figure 1.3	Developmental stages of oligodendrocytes lineage development	11
Figure 1.4	Structure of myelin sheath	12
Figure 1.5	Model showing myelin wrapping around axon	23
Figure 1.6	Schematic of the oligodendrocyte lineage showing some of the intrinsic and extrinsic factors that regulates oligodendrocyte differentiation and the myelination of axons	23
Figure 1.7	Structure and Splicing of MeCP2	38
Figure 1.8	MeCP2 function in gene regulation and chromatin organization	39
Figure 2.1	Morphological, Immunocytochemical and Biochemical characterization of oligodendrocytes developmental stages	65
Figure 2.2	MeCP2 expression in oligodendrocytes lineage cells	66
Figure 2.3	Change in cell morphology and increased myelin genes mRNA expression by MeCP2 siRNA in oligodendrocytes.	67
Figure 2.4	Expression of mRNAs for BDNF, YY1 and ID4 in oligodendrocytes treated with MeCP2 siRNA	68
Figure 2.5	Knock Down of MeCP2 expression in cultured oligodendrocytes	68

Figure 2.6	Myelin proteins expression in MeCP2 deficient oligodendrocytes	69
Figure 2.7	MeCP2 regulate the BDNF level in oligodendrocytes	70
Figure 2.8	MeCP2 regulate the oligodendrocytes precursor cells (OPCs) migration	71
Figure 2.9	Map of pMeCP2Y plasmid expressing MeCP2 fused with YFP	72
Figure 2.10	Plasmid isolation and confirmation	73
Figure 2.11	MeCP2 over expression in primary oligodendrocytes	74
Figure 3.1	Rat MBP Gene promoter sequence and CpG island prediction	82
Figure 3.2	Rat PLP Gene promoter sequence and CpG island prediction	83
Figure 3.3	Rat BDNF Gene promoter IV sequence and CpG island prediction	84
Figure 3.4	Genomic DNA isolation and Optimization of PCR for Promoter region primers	85
Figure 3.5	Optimization of sonication condition for oligodendrocytes chromatin shearing	85
Figure 3.6	MeCP2 bind to promoter regions of MBP gene	86
Figure 3.7	MeCP2 bind to promoter regions of PLP gene	87
Figure 3.8	MeCP2 bind to BDNF Promoter IV	88
Figure 4.1	MeCP2 expression in C6 glioma	101
Figure 4.2	MeCP2 Over expression in C6 glioma	102

Figure 4.3	Stable MeCP2 over expression in C6 glioma induce the morphological transformation	103
Figure 4.4	MeCP2 over expression inhibit C6 glioma growth proliferation	104
Figure 4.5	MeCP2 overexpression in C6 glioma suppress anchorage independent growth and sphere formation	105
Figure 4.6	MeCP2 overexpression reduces the C6 glioma adhesion to extracellular matrix fibronectin	106
Figure 4.7	MeCP2 over expression reduce C6 glioma migration and invasion	107
Figure 4.8	Figure 4.8: MeCP2 over expression suppress the pERK levels in C6 glioma	108
Figure 4.9	MeCP2 over expression in C6 glioma alter GFAP, BDNF and FAK expression	109
Figure 4.10	MeCP2 directly bind to GFAP and BDNF gene Promoters	110
Figure 4.11	MeCP2 Knock down in C6 glioma	111
Figure 4.12	MeCP2 knockdown increase the C6 glioma proliferation	112
Figure 4.13	MeCP2 knockdown regulates C6 glioma migration	113
Figure 4.14	MeCP2 knock down do not alter the C6 glioma adhesion to extracellular matrix fibronectin	114
Figure 4.15	MeCP2 knock down alter pERK, GFAP and BDNF proteins level in C6 glioma	115
Figure 4.16	Myelin gene expression in MeCP2 over expressing C6 glioma	116

Figure 4.17	Myelin gene expression in MeCP2 Knock down C6 glioma	117
Figure 4.18	MeCP2 does not bind to MBP and PLP gene Promoters in C6 glioma	118
Figure 5.1	MeCP2 negatively regulate myelin gene expression in cultured rat oligodendrocytes	122
Figure 5.2	MeCP2 inhibit the malignant phenotype of C6 glioma	124

LIST OF TABLES

Tables	Title	Page
2.1	Primers used for Real time PCR	75
3.1	Sequence of primers used for ChIP-PCR	84
4.1	Primers list used for real time PCR	119
4.2	Primers list used for ChIP PCR	120